The combination of CuP/Er with an anti‐PD‐L1 antibody (αPD‐L1) potently regressed tumors and prevented tumor metastasis via synergizing T cell proliferation by CuP/Er and T cell reinvigoration by ICB to afford potent cancer immunotherapy. This evidence concerns the gene CD274 and neoplasm.